SG Analytics (SGA) helps you generate evidence of the value of a new drug or product for reimbursement and healthcare payers using artificial intelligence (AI)/machine language (ML) tools for crisp and precise solutions.
HEOR is conducted to analyze DALY and positive health outcomes by studying healthcare providers, hospitals, clinics, managed care, and public health promotion activities in different set-ups.
SGA started its health economics and outcomes research (HEOR) services and solutions in 2020. It has one of the most sought-after services from our pharmaceutical clients. Our health economics and outcomes research consultants use ML tools to scrape precise real-world data pertinent to medical research and disease areas and transform a cumbersome process into a much easier, white-labeled customized report.
The relevance of HEOR is increasing with each passing day, as it provides valuable information to the decision-makers in drug, diagnostics, and medical product companies, as well as healthcare providers and patients for optimal allocation of healthcare resources. Health economics outcomes research is a function within a pharma or life sciences company that supports strategy and marketing teams to generate evidence of the value of a new drug or diagnostic kit or product or other intervention, which will need reimbursement in the future. Millions of dollars are spent on getting cumbersome HEOR reports from the market.
Why SGA
Industry Leaders
SGA thrives by its brand promise - Life is Possible, and is recognized as the trusted healthcare market research consulting company in the USA.
12+ Languages
Language capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English experts (US/UK).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL capability of more than 700, along with analytical and ML/AI capabilities, helps in presenting credible competitive information.
Whitepapers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
Whitepapers
The Blue Ocean Strategy in the Pharmaceutical Industry: What Is the Blue Ocean Strategy About?
Blue ocean refers to a new market that presents low competition, is less crowded, and is open to accommodate new innovations and marketing opportunities....
Whitepapers
What Happens When You Invest in Healthcare Consulting and Analytics?
Healthcare providers who are struggling with high-volume complex data are feeling the need for assistance with data convergence and management. With...
We strongly believe in women power. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
